Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Fineline Cube May 22, 2026
Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Fineline Cube May 22, 2026
Policy / Regulatory

Hainan Medical Products Administration Issues Guidelines for Imported Drug Management

Fineline Cube Jul 4, 2022

The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...

Company Drug

Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors

Fineline Cube Jul 4, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...

Company Drug

Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide

Fineline Cube Jul 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...

Company Deals

Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China

Fineline Cube Jul 4, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...

Company

Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations

Fineline Cube Jul 4, 2022

California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of...

Company Deals

Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s

Fineline Cube Jul 4, 2022

Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...

Policy / Regulatory

NMPA Releases Plans to Support HK and Macau Drug, Device Production in Mainland Cities

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released two implementation plans aimed at supporting Hong...

Company Drug

Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials

Fineline Cube Jul 1, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...

Company Drug

Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...

Company R&D

Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection

Fineline Cube Jul 1, 2022

Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...

Company Deals

Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing

Fineline Cube Jul 1, 2022

China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...

Policy / Regulatory

NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...

Company Drug

BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study

Fineline Cube Jul 1, 2022

BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...

Policy / Regulatory

NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...

Company Drug

Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval

Fineline Cube Jul 1, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...

Drug

Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT

Fineline Cube Jul 1, 2022

China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...

Company Drug

Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...

Company Deals

Corestar Biotech Secures Series A Funding for POCT R&D Expansion

Fineline Cube Jun 30, 2022

Shenzhen-based point-of-care testing (POCT) specialist Corestar Biotechnology Co., Ltd has raised “tens of millions” of...

Company Deals

Great Robotics Raises RMB 100M for Surgical Robot Development

Fineline Cube Jun 30, 2022

Great Robotics, a Beijing-based medical robotics company, has reportedly raised close to RMB 100 million...

Company Deals

Visum Pharma Series B+ Financing to Advance R&D and GMP Workshop Construction

Fineline Cube Jun 30, 2022

Visum Pharmaceutical Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in...

Posts pagination

1 … 659 660 661 … 670

Recent updates

  • Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment
  • Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer
  • Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU
  • Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC
  • Bayer’s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Company Drug

Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU

Company Drug

Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.